Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma

被引:89
作者
von Rahden, BHA
Stein, HJ
Pühringer, F
Koch, I
Langer, R
Piontek, G
Siewert, JR
Höfler, H
Sarbia, M
机构
[1] Tech Univ Munich, Dept Surg, D-8000 Munich, Germany
[2] Tech Univ Munich, Inst Pathol & Pathol Anat, D-8000 Munich, Germany
关键词
D O I
10.1158/0008-5472.CAN-04-1107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclooxygenases (COX), especially COX-2, are considered to be involved in carcinogenesis. Our study was initiated to test whether expression of COX isoforms (COX-1 and COX-2) is linked to expression of potent inducers of angiogenesis [vascular endothelial growth factor (VEGF)-A] and lymphangiogenesis (VEGF-C) in esophageal adenocarcinoma. One hundred twenty-three esophageal adenocarcinomas were investigated by means of quantitative reverse transcription-PCR for expression of COX-1, COX-2, VEGF-A, and VEGF-C. Additionally, COX-2 protein expression was determined using immunohistochemistry. Three esophageal cancer cell lines (OE-33, OSC-1, and OSC-2) were treated with COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) and the effect on expression of the four genes was determined. COX-2 protein expression was found in all carcinomas under analysis. RNA expression levels of COX-1 and COX-2 varied markedly in carcinoma tissues and correlated significantly with each other (P < 0.001, r = 0.726). Furthermore, COX expression correlated with expression of VEGF-A (COX-1: P < 0.001, r = 0.753; COX-2: P < 0.001, r = 0.764) and VEGF-C (COX-1: P < 0.001, r = 0.778; COX-2: P < 0.001; r = 0.613). Exposure of esophageal cancer cell lines OE-33, OSC-1, and OSC-2 with three COX-inhibiting substances (diclofenac, rofecoxib, and SC-560) resulted in significantly reduced expression of VEGF-A and VEGF-C. In conclusion, our data suggest that both COX isoforms may be involved in the pathogenesis of esophageal adenocarcinoma, as they are linked to the expression of important modulators of angiogenesis (VEGF-A) and lymphangiogenesis (VEGF-C).
引用
收藏
页码:5038 / 5044
页数:7
相关论文
共 22 条
[1]   High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors [J].
Bauer, AK ;
Dwyer-Nield, LD ;
Malkinson, AM .
CARCINOGENESIS, 2000, 21 (04) :543-550
[2]   Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus [J].
Buskens, CJ ;
Van Rees, BP ;
Sivula, A ;
Reitsma, JB ;
Haglund, C ;
Bosma, PJ ;
Offerhaus, GJA ;
Van Lanschot, JJB ;
Ristimäki, A .
GASTROENTEROLOGY, 2002, 122 (07) :1800-1807
[3]   Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus [J].
Buttar, NS ;
Wang, KK ;
Leontovich, O ;
Westcott, JY ;
Pacifico, RJ ;
Anderson, MA ;
Krishnadath, KK ;
Lutzke, LS ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (04) :1101-1112
[4]  
Chulada PC, 2000, CANCER RES, V60, P4705
[5]   Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer [J].
Cianchi, F ;
Cortesini, C ;
Bechi, P ;
Fantappié, O ;
Messerini, L ;
Vannacci, A ;
Sardi, I ;
Baroni, G ;
Boddi, V ;
Mazzanti, R ;
Masini, E .
GASTROENTEROLOGY, 2001, 121 (06) :1339-1347
[6]   Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis [J].
Corley, DA ;
Kerlikowske, K ;
Verma, R ;
Buffler, P .
GASTROENTEROLOGY, 2003, 124 (01) :47-56
[7]  
Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.3.CO
[8]  
2-U
[9]   Barrett's-related esophageal cancer: Has the final hurdle been cleared, now paving the way for human chemoprevention trials? [J].
Fennerty, MB .
GASTROENTEROLOGY, 2002, 122 (04) :1172-1175
[10]   The contributions of cyclooxygenase-2 to tumor angiogenesis [J].
Gately, S .
CANCER AND METASTASIS REVIEWS, 2000, 19 (1-2) :19-27